ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Development and validation of an immune-related gene signature for prognosis in Lung adenocarcinoma

Guo, Zehuai; Qi, Xiangjun; Li, Zeyun; Yang, Jianying; Sun, Zhe; Li, Peiqin; Chen, Ming; Cao, Yang*广州中医药大学; 1; y
IET Systems Biology2023-2DOI: 10.1049/syb2.12057
17阅读
引用收藏
分享

摘要

The most common type of lung cancer tissue is lung adenocarcinoma. The TCGA-LUAD cohort retrieved from the TCGA dataset was considered the internal training cohort, while GSE68465 and GSE13213 datasets from the GEO database were used as the external test cohort. The TCGA-LUAD cohort was classified into two immune subtypes using single-sample gene set enrichment analysis of the immune gene set and unsupervised clustering analysis. The ESTIMATE algorithm, the CIBERSORT algorithm, and HLA family expression levels again validated the reliability of this typing. We performed Venn analysis using immune-related genes from the immport dataset and differentially expressed genes from the subtypes to retrieve differentially expressed immune genes (DEIGs). In addition, DEIGs were used to construct a prognostic model with the least absolute shrinkage and selection operator regression analysis. A reliable risk model consisting of 11 DEIGs, including S100P, INHA, SEMA7A, INSL4, CD40LG, AGER, SERPIND1, CD1D, CX3CR1, SFTPD, and CD79A, was then built, and its reliability was further confirmed by ROC curve and calibration plot analysis. The high-risk score subgroup had a poor prognosis and a lower tumour immune dysfunction and exclusion score, indicating a greater likelihood of anti-PD-1/cytotoxic T lymphocyte antigen 4 benefit.

学科与关键词

关键词
bioinformaticsimmune-related geneimmunotherapylung adenocarcinomaprognosisssGSEA
相关
加载中…
  • Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
    Li, Na; Wang, Jiahong; Zhan, Xianquan*Frontiers in Immunology, 2021, 12: 752643.被引 19
  • Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
    Yi, Ming; Li, Anping; Zhou, Linghui; Chu, Qian; Luo, Suxia*; Wu, Kongming*Cancer Immunol Immunother, 2021, 70(6): 1705-1719.
  • Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma
    Cao, Kui; Liu, Mingdong; Ma, Keru; Jiang, Xiangyu; Ma, Jianqun*; Zhu, Jinhong*Cancer Immunology, Immunotherapy, 2022, 71(6): 1295-1311.被引 14
查看全部 →

发表信息

论文状态
公开发表
期刊
IET Systems Biology
发表日期
2023-02
卷期
第 17 卷, 第 1 期
页码
27-38
DOI
10.1049/syb2.12057
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81973815]

作者

  • G

    Guo, Zehuai (第一作者)

    1 · guangzhou univ chinese med

  • Q

    Qi, Xiangjun

    1 · guangzhou univ chinese med

查看全部 8 位作者收起作者
  • L

    Li, Zeyun

    1 · guangzhou univ chinese med

  • Y

    Yang, Jianying

    1 · guangzhou univ chinese med

  • S

    Sun, Zhe

    1 · guangzhou univ chinese med

  • L

    Li, Peiqin

    1 · guangzhou univ chinese med

  • C

    Chen, Ming

    1 · guangzhou univ chinese med

  • C

    Cao, Yang (通讯)

    1 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417